IPA - revenue streams, services,... Sometimes I read comments here and wonder if I have confused stock symbols.
This company is not a biotech awaiting clinical trial results.
I think their revenue streams are intact.
They're going to be just fine. Recently some share holders were obviously sell, maybe shorting was taking place. Maybe that will continue. But the core business hasn't changed.
They describe themselves as:
ImmunoPrecise’s proprietary technologies and products are positioned on the leading edge of antibody development, innovating our industry as a single source provider of the full complement of antibody discovery platforms. As an investor in ImmunoPrecise Antibodies, you’re joining us at the forefront of new, exciting, and valuable advancements in next-generation antibody discovery.